Literature DB >> 10514450

Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer.

J Grober1, I Zaghini, H Fujii, S A Jones, S A Kliewer, T M Willson, T Ono, P Besnard.   

Abstract

Intestinal bile acid-binding protein (I-BABP) is a cytosolic protein that binds bile acids (BAs) with a high affinity. In the small intestine, its expression is restricted to the ileum where it is involved in the enterohepatic circulation of BAs. Using the human enterocyte-like Caco-2 cell line, we have recently shown that BAs increased I-BABP gene expression. To determine whether this regulation occurs in vivo, the effect of BA depletion or supplementation was studied in mice. A dramatic drop in I-BABP mRNA levels was observed in mice treated with the BA-binding resin cholestyramine, whereas an increase was found in animals fed with taurocholic acid. BAs are physiological ligands for the nuclear farnesoid X receptor (FXR). Both FXR and I-BABP are co-expressed along the small intestine and in Caco-2 cells. To determine the role of FXR in the regulation of I-BABP expression, the promoter of the human I-BABP gene was cloned. In Caco-2 cells, cotransfection of FXR and RXRalpha is required to obtain the full transactivation of the I-BABP promoter by BAs. Deletion and mutation analyses demonstrate that the FXR/RXRalpha heterodimer activates transcription through an inverted repeat bile acid responsive element located in position -160/-148 of the human I-BABP promoter. In conclusion, we show that FXR is a physiological BA sensor that is likely to play an essential role in BA homeostasis through the regulation of genes involved in their enterohepatic circulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514450     DOI: 10.1074/jbc.274.42.29749

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

Review 1.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

Review 2.  Small bowel review: Normal physiology, part 1.

Authors:  Alan B R Thomson; Laurie Drozdowski; Claudiu Iordache; Ben K A Thomson; Severine Vermeire; M Tom Clandinin; Gary Wild
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

Review 3.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

4.  The farnesoid X receptor regulates transcription of 3beta-hydroxysteroid dehydrogenase type 2 in human adrenal cells.

Authors:  Yewei Xing; Karla Saner-Amigh; Yasuhiro Nakamura; Margaret M Hinshelwood; Bruce R Carr; J Ian Mason; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

5.  A nuclear receptor ligand down-regulates cytosolic phospholipase A2 expression to reduce bile acid-induced cyclooxygenase 2 activity in cholangiocytes: implications of anticarcinogenic action of farnesoid X receptor agonists.

Authors:  Daisuke Komichi; Susumu Tazuma; Tomoji Nishioka; Hideyuki Hyogo; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

6.  LXR alpha transactivates mouse organic solute transporter alpha and beta via IR-1 elements shared with FXR.

Authors:  Masae Okuwaki; Tappei Takada; Yuki Iwayanagi; Saori Koh; Yoshiaki Kariya; Hiroshi Fujii; Hiroshi Suzuki
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

7.  FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

Authors:  Ann M Bailey; Le Zhan; Dipen Maru; Imad Shureiqi; Curtis R Pickering; Galina Kiriakova; Julie Izzo; Nan He; Caimiao Wei; Veerabhadran Baladandayuthapani; Han Liang; Scott Kopetz; Garth Powis; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-31       Impact factor: 4.052

8.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.

Authors:  Helen B Hartman; Stephen J Gardell; Chris J Petucci; Shuguang Wang; Julie A Krueger; Mark J Evans
Journal:  J Lipid Res       Date:  2009-01-27       Impact factor: 5.922

Review 9.  The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism.

Authors:  Folkert Kuipers; Thierry Claudel; Ekkehard Sturm; Bart Staels
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

10.  Sequencing and chromosomal localization of Fabp6 and an intronless Fabp6 segment in the rat.

Authors:  Anita Bonné; Claudia Gösele; Maria den Bieman; Gert Gillissen; Thomas Kreitler; Michal Pravenec; Vladimir Kren; Hein van Lith; Bert van Zutphen
Journal:  Mol Biol Rep       Date:  2003-09       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.